Cargando…

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

Lasmiditan, a serotonin 5-HT(1F) receptor agonist, was effective for acute treatment of patients with migraine in a phase 3 double-blind randomized controlled study. The current study was designed to replicate these findings in a generalizable population of patients with migraine, including those wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goadsby, Peter J, Wietecha, Linda A, Dennehy, Ellen B, Kuca, Bernice, Case, Michael G, Aurora, Sheena K, Gaul, Charly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620826/ https://www.ncbi.nlm.nih.gov/pubmed/31132795 http://dx.doi.org/10.1093/brain/awz134

Ejemplares similares

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
por: Kuca, Bernice, et al.
Publicado: (2018)

Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
por: Shapiro, Robert E., et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
por: Detke, Holland C., et al.
Publicado: (2018)

The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020)

Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls
por: Pearlman, Eric M., et al.
Publicado: (2020)

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial
por: Gaul, Charly, et al.
Publicado: (2015)

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies
por: Ashina, Messoud, et al.
Publicado: (2019)

Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Lasmiditan: A New Promising Drug in Migraine
por: Prakash, Sanjay, et al.
Publicado: (2021)

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo‐Controlled, Double‐Blind Phase 2 Trial
por: Pignolo, Robert J., et al.
Publicado: (2022)

Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain
por: Konno, Shinichi, et al.
Publicado: (2016)

Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial
por: Kita, Toshihiro, et al.
Publicado: (2022)

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
por: Rizzoli, Paul B
Publicado: (2014)

Budget impact of lasmiditan for the acute treatment of migraine in the United States
por: Milev, Sandra, et al.
Publicado: (2021)

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
por: Blumenfeld, Andrew, et al.
Publicado: (2023)

EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
por: Goadsby, P, et al.
Publicado: (2014)

A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma
por: Benson, Al B., et al.
Publicado: (2017)

Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial
por: Pijpers, Judith A, et al.
Publicado: (2019)

Adjuvant use of melatonin for pain management in dysmenorrhea — a randomized double-blinded, placebo-controlled trial
por: Söderman, Lisa, et al.
Publicado: (2021)

75200 Fecal Microbiota Transplantation to Prevent Infections in Patients with Acute Myeloid Leukemia: A Double-Blind Randomized Placebo-Controlled Phase 2 Clinical Trial
por: Ebadi, Armin Rashidiryam, et al.
Publicado: (2021)

Safety and pharmacokinetics of EP-104IAR (sustained-release fluticasone propionate) in knee osteoarthritis: A randomized, double-blind, placebo-controlled phase 1 trial
por: Malone, Amanda, et al.
Publicado: (2021)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)
por: Loo, Li Shen, et al.
Publicado: (2019)

Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study
por: Pini, Luigi Alberto, et al.
Publicado: (2012)

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: Tassorelli, C, et al.
Publicado: (2021)

Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
por: DuBois, Janet, et al.
Publicado: (2021)

Bacterial lysate add‐on therapy to reduce exacerbations in severe asthma: A double‐blind placebo‐controlled trial
por: de Boer, Geertje M., et al.
Publicado: (2021)

Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study
por: Wilbraham, Darren, et al.
Publicado: (2019)

A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study
por: Riedel, Richard F., et al.
Publicado: (2020)

The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study
por: Müller, Fabian, et al.
Publicado: (2022)

The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
por: Tfelt-Hansen, Peer C., et al.
Publicado: (2012)

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
por: Oswald, Jessica C, et al.
Publicado: (2018)

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
por: Anderson, Christopher C, et al.
Publicado: (2023)

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
por: Krege, John H, et al.
Publicado: (2019)

Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis
por: Ahsan, Marya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6d2dlnsalk2esnkub37ohsa484